Chardan Capital Increases Lexeo Therapeutics (NASDAQ:LXEO) Price Target to $25.00
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) had its price objective increased by equities researchers at Chardan Capital from $23.00 to $25.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price indicates a potential upside of 227.23% from […]
More Stories
Federal Judge Declines to Block Border Wall Construction on Arizona Tribal Land
By Aldgra Fredly A federal judge on Aug. 14 refused to block the Trump administration from building a border wall...
Wall Street Review: S&P 500 Hits Record High as Inflation Cools, Earnings Stay Strong
By Panos Mourdoukoutas The S&P 500 climbed to a fresh record high this week, powered by new data showing inflation...
Fauci Refuses to Appear Before 2nd Senate Panel After Contempt Vote
By Tom Ozimek Dr. Anthony Fauci has declined a request to appear voluntarily before a second Senate panel, days after...
HHS Report on Alleged Pediatric Gender-Treatment Fraud: 5 Key Takeaways
By Stacy Robinson A report released Aug. 13 by the Department of Health and Human Services (HHS) has shined a...
North Korea Threatens Stronger Deterrence Ahead of US–South Korea Military Drills
By Victoria Friedman Pyongyang has denounced the upcoming annual joint U.S.–South Korean military drills on the peninsula, calling them provocative...
Trump Says He’ll Declare the Hormuz Strait a US Territory ‘Pretty Soon’
By Emel Akan President Donald Trump announced on Friday his intention to declare the Strait of Hormuz a U.S. territory,...